James M. Frates's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 9,768 Common Stock done at an average price of $32.3 . Disclosure was reported to the exchange on Sept. 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.27 per share. | 10 Sep 2026 | 9,768 | 234,667 | - | 32.3 | 315,195 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.23 per share. | 10 Sep 2026 | 1,042 | 233,625 | - | 33.2 | 34,626 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2026 | 22,807 | 244,435 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 05 Mar 2026 | 143,985 | 143,985 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 95,990 | 261,628 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 95,990 | 261,628 | - | 0 | - | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.52 per share. | 02 Mar 2026 | 7,909 | 165,638 | - | 14.5 | 114,851 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.52 per share. | 02 Mar 2026 | 7,909 | 165,638 | - | 14.5 | 114,851 | - |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.65 per share. | 02 Feb 2026 | 3,557 | 173,547 | - | 14.6 | 52,097 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.65 per share. | 02 Feb 2026 | 3,557 | 173,547 | - | 14.6 | 52,097 | - |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.11 per share. | 06 Jan 2026 | 3,326 | 177,104 | - | 11.1 | 36,954 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.11 per share. | 06 Jan 2026 | 3,326 | 177,104 | - | 11.1 | 36,954 | - |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.65 per share. | 30 Sep 2025 | 10,558 | 280,430 | - | 14.6 | 154,650 | Common Stock |
| Sage Therapeutics Inc | James M. Frates | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2025 | 21,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | James M. Frates | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Jul 2025 | 19,154 | 0 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | James M. Frates | Director | 31 Jul 2025 | 2,845 | 0 (0%) | 0% | - | Common Stock | ||
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 21,500 | 21,500 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 31 Mar 2025 | 10,896 | 290,988 | - | 3.5 | 37,806 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 301,884 | - | 0 | Common Stock | |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,154 | 19,154 | - | - | Stock Options (Right to buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 12 Sep 2024 | 40,000 | 233,464 | - | 2.5 | 101,368 | Common Stock |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 91,180 | 225,964 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 1,792 | 134,784 | - | 18.7 | 33,560 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 26 Feb 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 40,000 | 152,035 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 2,716 | 112,035 | - | 16.3 | 44,347 | Common Stock |
| Sage Therapeutics Inc | M. Frates James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 4,925 | 4,925 | - | - | Stock Options (Right to buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2023 | 11,072 | 11,072 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 106,341 | - | 6.9 | 124,975 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 73,841 | - | 6.9 | 124,975 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | ||
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 16 May 2023 | 32,500 | 382,000 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 May 2023 | 32,500 | 88,176 | - | 6.9 | 223,600 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.93 per share. | 16 May 2023 | 32,000 | 56,176 | - | 26.9 | 861,651 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 16 May 2023 | 500 | 55,676 | - | 27.6 | 13,800 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 16 Mar 2023 | 97,500 | 97,500 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Mar 2023 | 32,500 | 66,509 | - | 6.9 | 223,600 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 16 Mar 2023 | 32,500 | 414,500 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 16 Mar 2023 | 30,796 | 35,713 | - | 31.9 | 981,139 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 16 Mar 2023 | 30,796 | 3,213 | - | 31.9 | 981,139 | - |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 21,667 | 55,676 | - | 0 | Common Stock | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 21,667 | 23,176 | - | 0 | - | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 16 Mar 2023 | 1,704 | 34,009 | - | 32.5 | 55,320 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 16 Mar 2023 | 1,704 | 1,509 | - | 32.5 | 55,320 | - |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,836 | 34,831 | - | 36.1 | 66,241 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 822 | 34,009 | - | 36.8 | 30,240 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 30 Dec 2022 | 5,000 | 36,667 | - | 6.9 | 34,400 | Common Stock |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 30 Dec 2022 | 5,000 | 447,000 | - | - | Stock Option (Right to Buy) | ||
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,947 | 9,947 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 11 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 31,667 | 31,667 | - | 0 | - | |
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 0 | - | - | Series C-1 Preferred Stock | ||
| Amylyx Pharma Inc | Mr. James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 19,482 | - | 0 | Common Stock |